Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Regeneron

spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi

, did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies. Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares. Regeneron shares spiked to a high of $145.81 on Thursday.